SG
CARM

StoneX Group’s Carisma Therapeutics CARM Stock Holding History

StoneX Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,732
Closed -$3.33K – 896
2025
Q1 		$3.33K Buy
+10,732
New +$4.75K ﹤0.01% 839
2023
Q1 		– Sell
-650
Closed -$7.92K – 478
2022
Q4 		$7.92K Buy
+650
New +$6.83K ﹤0.01% 466
2022
Q3 		– Sell
-745
Closed -$12.1K – 378
2022
Q2 		$12.1K Buy
+745
New +$8.53K ﹤0.01% 455

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

StoneX Group's CARM Position: Q2 2025 in Review

StoneX Group sold out of Carisma Therapeutics (CARM) in Q2 2025, closing a stake of 10,732 shares — an estimated $3.33K sold.

StoneX Group first reported a position in CARM in Q2 2022 and held it in 3 quarters. The position peaked at $12.1K in Q2 2022. 36 funds tracked by Wall St. Rank hold CARM as of Q2 2025.

  • StoneX Group reported no remaining Carisma Therapeutics position as of Q2 2025 after selling out during the quarter.
  • StoneX Group sold 10,732 Carisma Therapeutics shares in Q2 2025, an estimated $3.33K.
  • StoneX Group first reported a position in Carisma Therapeutics in Q2 2022 and held it in 3 quarters.
  • StoneX Group's Carisma Therapeutics position peaked at $12.1K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2025.

Based on StoneX Group's 13F filing for Q2 2025, filed 13 Aug 2025.